Royal

Goldman Sachs Group Inc. Sells 26,421 Shares of Trevena, Inc. (NASDAQ: TRVN)

Goldman Sachs Group Inc. decreased its position in shares of Trevena, Inc. (NASDAQ:TRVN) by 9.7% during the 2nd quarter, Holdings Channel reports. The fund owned 245,447 shares of the biopharmaceutical company’s stock after selling 26,421 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Trevena were worth $415,000 at the end of the most […] The post Goldman Sachs Group Inc. Sells 26,421 Shares of Trevena, Inc. (NASDAQ:TRVN) appeared first on ETF Daily News. ...

Goldman Sachs Group Inc. reduced its placement in shares of Trevena, Inc.(NASDAQ: TRVN )by 9.7%throughout the 2nd quarter, Holdings Channel records. The fund had 245,447 shares of the biopharmaceutical business’s supply after offering 26,421 shares throughout the quarter. Goldman Sachs Group Inc.’s holdings in Trevena deserved $415,000 at the end of one of the most current quarter. A variety of various other institutional capitalists have actually additionally lately contributed to or minimized their risks in the supply. Wellington Shields Capital Management LLC got a brand-new setting in Trevena throughout the 2nd quarter worth about $27,000. Northern Trust Corp elevated its holdings in Trevena by 102.1% throughout the 2nd quarter. Northern Trust Corp currently has 582,999 shares of the biopharmaceutical firm’s supply worth $985,000 after acquiring an added 294,481 shares throughout the duration. Geode Capital Management LLC elevated its holdings in Trevena by 93.0% throughout the 2nd quarter. Geode Capital Management LLC currently has 2,721,744 shares of the biopharmaceutical business’s supply worth $4,599,000 after acquiring an added 1,311,611 shares throughout the duration. Lead Group Inc. increased its holdings in Trevena by 8.1% throughout the 2nd quarter. Lead Group Inc. currently has 7,697,154 shares of the biopharmaceutical business’s supply worth $13,009,000 after purchasing an extra 574,997 shares throughout the duration. Ultimately, ProShare Advisors LLC got a brand-new risk in Trevena throughout the 2nd quarter worth around $72,000. 21.61% of the supply is presently possessed by institutional capitalists and also hedge funds.

NASDAQ TRVN opened up at $0.68 on Wednesday. Trevena, Inc. has a 12-month low of $0.63 and also a 12-month high of $3.10. The firm has a market capitalization of $111.87 million, a PE proportion of -2.19 and also a beta of 2.23. The company’s 50 day relocating standard is $0.97 as well as its 200-day relocating standard is $1.33.

Trevena (NASDAQ: TRVN) last published its quarterly profits information on Monday, November 15th. The biopharmaceutical firm reported ($0.08) incomes per share (EPS) for the quarter, defeating the Zacks’ agreement price quote of ($0.09) by $0.01. Trevena had an unfavorable internet margin of 7,771.74% and also an adverse return on equity of 53.47%. The firm had profits of $0.18 million for the quarter, contrasted to the agreement quote of $1.16 million. Throughout the exact same duration in 2015, the firm made ($0.04) revenues per share. Typically, sell-side experts forecast that Trevena, Inc. will certainly upload -0.33 incomes per share for the existing.

Numerous experts have actually discussed TRVN shares. JMP Securities reiterated a “acquire” ranking as well as established a $6.00 target rate on shares of Trevena in a record on Tuesday, September 7th. Oppenheimer reiterated a “hold” ranking on shares of Trevena in a record on Friday, October 1st. Lastly, Zacks Investment Research updated shares of Trevena from a “sell” ranking to a “hold” ranking in a record on Thursday, October 14th.

Regarding Trevena

Trevena, Inc takes part in the advancement and also commercialization of unique medications for individuals impacted by main nerves conditions. Its item prospects consist of Oliceridine shot, TRV250, TRV734, and also TRV045. The business was established by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A.

Featured Story: Marijuana Stocks Future Looks Bright

Leave a Reply

Available for Amazon Prime